1. Home
  2. ARVN vs HQ Comparison

ARVN vs HQ Comparison

Compare ARVN & HQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.57

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$24.48

Market Cap

562.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARVN
HQ
Founded
2015
2018
Country
United States
Singapore
Employees
N/A
44
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
562.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
HQ
Price
$7.57
$24.48
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$15.05
N/A
AVG Volume (30 Days)
694.3K
626.0K
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$8.29
52 Week High
$14.22
$19.71

Technical Indicators

Market Signals
Indicator
ARVN
HQ
Relative Strength Index (RSI) 37.96 79.41
Support Level $7.35 $9.30
Resistance Level $10.18 N/A
Average True Range (ATR) 0.42 2.12
MACD 0.05 1.12
Stochastic Oscillator 31.43 97.84

Price Performance

Historical Comparison
ARVN
HQ

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

Share on Social Networks: